Site-Stability Guidance Arranges Drugs Into Three Risk Groups - Revised Draft
Executive Summary
Drugs could be classified into three risk categories for the purposes of site-stability data submissions based on potential adverse effects of drug substance and product stability due to site-transfer, FDA suggests in revisions to a draft guidance.
You may also be interested in...
Certificates Of Analysis Suggested As Alternative To Site-Specific Stability
Certificates of analysis from three commercial-scale validation batches could provide assurance that technology transfer has been successfully completed from a pilot manufacturing site to a commercial site, the Pharmaceutical Science Advisory Committee Site Specific Subcommittee determined Sept. 22.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011